There Antibodies. Monoclonal anti-p185?eu antibody 7.16.4-IgG (19) was purified by protein A affinity chromatography from ascites fluid. Antiserum to a synthetic peptide corresponding to the C-terminal 15 amino acids of human pl85neu was raised in rabbits injected with the immunogenic peptide coupled to thyroglobulin with maleimidobenzoyl-N-hydroxysuccinimide ester (Pierce). Monoclonal anti-phosphotyrosine antibody 1G2 (20) was purified from ascites fluid.
A variety of genetic methods including gene transfer, mutational analysis, and low-stringency hybridization have made it possible to isolate a group of genes that encode transmembrane proteins having the attributes of growth factor receptors. This growing list includes the protooncogenes neu (1-3), c-kit (4), ros (5), met (6) , trk (7) , ret (8) , and other genes such as eph (9) , fur (10) , and the Drosophila sevenless gene (11) . Most of these putative receptors carry a tyrosine-specific protein kinase function in their cytoplasmic portions. Some of these proteins are overexpressed in neoplastic tissues (12) (13) (14) , suggesting a role in growth regulation. Perhaps the most compelling examples are the neu and kit protooncogenes that display remarkable structural homology with established receptors for the peptide growth factors epidermal growth factor (EGF) and colony-stimulating factor 1 (CSF-1) (15) .
We have sought to establish methodological approaches for detection of ligands to such putative receptors. In practice, systematic screening of potential sources of the ligands calls for assays that are sensitive to low concentrations of ligands and at the same time capable of reliable detection of ligand when it is present in a complex mixture of unfractionated biological molecules such as tissue extracts or body fluids. Using the neu protooncogene as a model system, we present here several independent detection methods that suggest that a candidate ligand of the neu-encoded oncoprotein is secreted by fibroblasts upon transformation by ras oncogenes.
MATERIALS AND METHODS Materials. Affinity-purified goat anti-mouse IgG was from Fischer and it was radiolabeled with Na125I (Amersham) by the chloramine-T method (16) . Radiolabeled protein A and "pi were from New England Nuclear (DuPont).
Cell Lines. The DHER-G8 cell line is a derivative of NIH 3T3 fibroblasts transfected with a genomic clone of the normal rat neu gene and selected for overexpression (17) . Rat-1-EJ cells are rat fibroblasts transfected with an activated Ha-ras gene (pUC-EJ 6.6; ref. 18 ). Other cell lines were obtained from the American Type Culture Collection.
Antibodies. Monoclonal anti-p185?eu antibody 7.16.4-IgG (19) was purified by protein A affinity chromatography from ascites fluid. Antiserum to a synthetic peptide corresponding to the C-terminal 15 amino acids of human pl85neu was raised in rabbits injected with the immunogenic peptide coupled to thyroglobulin with maleimidobenzoyl-N-hydroxysuccinimide ester (Pierce) . Monoclonal anti-phosphotyrosine antibody 1G2 (20) was purified from ascites fluid.
Plasma Membrane Preparation. The procedure described before (4) was used to obtain purified plasma membrane fraction from DHFR-G8 cells.
Conditioned Media. Cells were grown to confluence in 175-cm2 flasks (Falcon), washed with phosphate-buffered saline, and left in serum-free medium for 10-16 hr. The medium was discarded and replaced by fresh serum-free medium that was collected after 3 days in culture. The conditioned medium was cleared from cells and concentrated 100-fold in an Amicon ultrafiltration cell through a YM2 membrane.
p185"" Down-Regulation Assay. Confluent monolayers of Rat-1 fibroblasts in 24-well dishes (Costar) were washed with Dulbecco's modified Eagle's medium (DMEM) and then incubated with 0.2 ml of binding buffer [DMEM supplemented with 20 mM Hepes (pH 7.5) and 0.1% bovine serum albumin] with or without conditioned medium and suramin (2 mM). After a 90-min incubation at 370C, the monolayers were washed with DMEM and incubated at 4°C with 3 ,ug of the 7.16.4 monoclonal anti-p185neu antibody per ml of binding buffer. Cell-bound antibody was determined after 2 hr by a 45-min incubation at cold with 125I-labeled protein A.
In Vitro Kinase Assay. Aliquots (50 ,g; 20 ,ul) of purified plasma membrane fraction were incubated with an equal volume of concentrated conditioned medium in a buffer containing 20 mM Hepes (pH 7.5) and bovine serum albumin (1 mg/ml) in the presence or absence of suramin (2 mM).
After 30 min of incubation, the membranes were solubilized by the addition of 0.2 ml of solubilization buffer (4) Metabolic Labeling with 32P and Immunoprecipitation. Subconfluent monolayers of cells cultured in 24-well dishes were labeled for 4-7 hr in DMEM without phosphate but supplemented with 1% dialyzed fetal calf serum and 0.8 mCi of 32p; per ml (NEN). The monolayers were then incubated at 220C in fresh medium that contained conditioned medium or growth factors. Fifteen minutes later, the cells were solubilized on ice with 0.4 ml of modified solubilization buffer containing 50 mM sodium pyrophosphate, 100 mM NaF, 5 mM EDTA, and 2 mM sodium orthovanadate. Undissolved material was removed and the cleared supernatant reacted (30 min at 4°C) with anti-phosphotyrosine antibody coupled to agarose. Immune complexes were washed by centrifugation at 4°C with 1 ml of high-, medium-, and low-salt buffers (4) . Elution of phosphotyrosine-containing antigens was achieved by mixing (30 min at 4°C) the final pellets with 1 ml of modified solubilization buffer supplemented with 50 mM p-nitrophenylphosphate. Supernatants were then mixed with rabbit anti-C-terminal peptide antibody coupled to Sepharose-protein A. After a 45-min reaction at 4°C, the beads were washed and immune complexes were subjected to gel electrophoresis as described above.
Infection of Hematopoietic Cells. A retrovirus containing the normal neu gene (21) and the neo selectable marker (22) was harvested from 4i-2 DOL34 cells and used to infect BAC1.2F5 murine macrophages (23) or BAF-3 prepro-B lymphocytes. Selection of neo-expressing clones was started 24 hr later by the addition of G418 (GIBCO) at a concentration of 2 mg/ml. Individual G418-resistant clones were isolated 2 weeks later and tested for expression of pl85neu by means of immunoprecipitation and self-phosphorylation within the immune complex.
Western Blot Analysis. Proteins resolved by polyacrylamide gel electrophoresis were transferred onto a nitrocellulose filter. The filter was then saturated by incubation with bovine serum albumin (5% in 50 mM Hepes, pH 7.5/150 mM NaCl) and reacted for 8 hr with the anti-phosphotyrosine antibody at 2 ,ug/ml. Radiolabeled goat anti-mouse antibody (400,000 cpm/ml) was allowed to react for 3 hr with the washed filter, and the filter was washed again before exposure at -70°C to an x-ray film. Cell Proliferation Assay. The MTT uptake method was used as described (24) except that the assay was done in medium that contained 0.5% calf serum, and the growth factors on which the cell lines are dependent were omitted.
RESULTS
Strategy for Ligand Detection. The putative receptor pl85neu was selected as an experimental system because ofits relatively detailed biochemical characterization (25, 26) and its possible involvement in human maligancies (13, 14) . Because of the extensive structural homology between pl85neu and EGF receptor, we hypothesized that its ligand would be related in structure and physiology to the ligands of EGF receptor: EGF/urogastrone, which is enriched in saliva and urine (27) , and transforming growth factor a (TGF-a), which is secreted by various carcinoma cell lines (28) . As a model system in which to test potential ligand-detection assays, we studied the EGF receptor displayed by human skin fibroblasts (data not shown). In addition, as a possible modulator of effects due to ligand-receptor interactions, we used the drug suramin. It has been shown that suramin inhibits binding of platelet-derived growth factor (PDGF) (29) and EGF (unpublished observation) to their receptors and therefore may well inhibit the binding of the putative ligand to pi85neu.
Down-Regulation of p18511 upon Treatment with Conditioned Medium Derived from ras-Transformed Fibroblasts.
Receptor down-regulation in response to exposure to its cognate ligand is a property shared by all known receptor tyrosine kinases. Moreover, the effect is specific to the ligand and in the case of the EGF receptor and pl85neu is not achieved through trans-modulation by heterologous receptors (30, 31) . The assay used here is based on quantitative immunological determination of surface-exposed receptors after incubation with the potential ligand at 37°C. When tested on human fibroblasts and human A431 cells, EGF at a concentration as low as 1 ng/ml could be readily detected by our down-regulation assay (data not shown). Analogously, when medium conditioned by Ha-ras-transformed fibroblasts (Rat-1-EJ) was incubated at 37°C with rat fibroblasts, we observed partial disappearance of cell surface pl85eu (Fig.  lA) . This effect was significantly inhibited by suramin at 2 mM, suggesting that it was due to receptor-ligand interactions. Furthermore, incubation at 4°C resulted in no apparent down-regulation of pl85neu (Fig. 1B) , and medium conditioned by untransformed rat fibroblasts was much less active, as shown in derived from the B-50 neuroblastoma line and the B-16 melanoma line were less active than Rat-1-EJ, whereas EGF and TGF-a at concentrations up to 100 ng/ml had no effect. Encouraged by these observations, we used alternative assays to examine the Rat-1-EJ-conditioned medium for the presence of the putative ligand.
Stimulation of Self-Phosphorylation of p1855 in Vitro.
Ligand-receptor interactions should lead to activation of the tyrosine-specific kinase function of pl851eu. However, less direct mechanisms may also lead to an apparently similar effect. Thus, TGF-a/EGF treatment of intact cells may induce phosphorylation of p185neu through the action of EGF receptor (30, 31) . Although there is no evidence that such trans-modulation also operates in broken cells, we sought to prevent such effects by the incubation of p185neu-rich plasma membranes with Rat-1-EJ-conditioned medium under conditions that do not allow protein phosphorylation. Accordingly, we omitted bivalent ions and nucleotides from the binding mixture. Later, the state of activation of the tyrosine kinase was assayed by the degree of self-phosphorylation within an immune complex.
As depicted in Fig. 2 , preincubation of p185neu-containing membranes with Rat-1-EJ-conditioned medium leads to selective enhanced self-phosphorylation of pl85neu. Slightly higher pl85neu phosphorylation is seen when the preincubation is done at 40C rather than at 370C, and it is completely abolished if preincubation with the conditioned medium is performed in the presence of suramin (Fig. 2) . EGF and conditioned medium of normal fibroblasts were inactive in this kinase activation assay, suggesting that a component of Rat-1-EJ-conditioned medium interacts directly with pl85neu to activate its enzymatic function.
This conclusion is underscored by the examination of the group of proteins in the molecular mass range of 80-100 kDa that coprecipitate with pl85neu in the in vitro kinase assay (Fig. 2) . These proteins reacted with two rabbit antisera directed to different peptide epitopes of the cytoplasmic domain of pl85neu but not with a series of monoclonal and polyclonal antibodies that are directed against the extracellular portion of pl85neu. In addition, the p80-p1OO phosphoproteins were capable of self-phosphorylation in vitro and their level was proportional to the level of expression of pl85neu in transfected mouse cells (data not shown). We conclude that p80-plOO phosphoproteins were Fig. 2 . Thus, the differential phosphorylation effect of p185 but not p80-plO0 is attributable to interaction of the putative ligand with the extracellular domain of p1851eu that is missing in the p80-p100 fragments.
Stimulation of Tyrosine Phosphorylation of p1851' in Human Mammary Carcinoma Cells. To test the ability of the conditioned medium of Rat-1-EJ cells to stimulate tyrosine phosphorylation of pl85neU in vivo, we metabolically labeled human mammary carcinoma cells (SKBR-3) with 32p;, challenged these cells with various conditioned media at 22TC, and analyzed tyrosine-phosphorylated p185ne1 by successive immunoprecipitations. In this cellular system, both media conditioned by Rat-1-EJ and sis-NRK cells stimulated tyrosine phosphorylation of pl85neu, whereas media conditioned by other cells were inactive (data not shown).
Since both ras-and sis-transformed fibroblasts secrete TGF-a (32, 33), we examined the possibility that the observed increased tyrosine phosphorylation of pl85neu was due to TGF-a acting through the EGF receptor. Accordingly, we used cells from another human mammary carcinoma line (MDA-MB453) that reportedly show undetectable levels of mRNA of the EGF receptor (13) Fig. 3A) , unlike the SKBR-3 cells. However, media conditioned by either ras-or sis-transformed fibroblasts, but not by untransformed rat fibroblasts, induced a significant increase in tyrosine phosphorylation ofpl85neu (Fig. 3A) . Furthermore, this effect was completely abolished by suramin, compatible with its origin in ligand-receptor interactions.
To examine the possibility that the effect of Rat-1-EJconditioned medium on p185neu phosphorylation is mediated by a receptor other than the EGF receptor and pl85neu itself, we used a truncation mutant of p185neu that lacks virtually all the extracellular putative ligand-binding domain but retains the rest of the molecule (35) . As shown in Fig. 3B (37). Thus, comparison of the response of such pl85neu-expressing hematopoietic cells with their parental nonexpressing cells should be a sensitive and specific liganddetection assay. For these reasons, we transduced the neu gene into two different hematopoietic lines: BAF-3, a precursor of B-lymphocytes (38) , and the BAC1.2F5 macrophage cell line (23) . Incubation of pl85neu-expressing BAF-3 cells (BAF-3/neu) or macrophages (BAC1/neu cells) with conditioned medium derived from Rat-1-EJ cells leads to elevation of tyrosine phosphorylation as evidenced in Fig. 4 . Other conditioned media, including those from untransformed fibroblasts, were inactive. We conclude that the mechanism responsible for the activation of pl85neu is shared by hematopoietic cells such as lymphocytes and macrophages that express pl85neu, further suggesting a direct effect that is mediated by the authentic neu ligand. The mitotic response of the factor-dependent B-lymphocyte and macrophage cell lines was determined by the cell proliferation assay of Mosmann (24) . In the absence of lymphokine, both BAF-3 and BAC1.2F5 cells show low if any proliferation. In addition, they both retain responsiveness to their normal mitogens, interleukin 3 and CSF-1, respectively (Table 1) . However, the response to conditioned medium of ras-transformed fibroblasts is quite different: whereas the parental lines are inhibited by the conditioned medium, their neu-expressing derivatives are mitogenically stimulated (Table 1) . We conclude that ras-transformed fibroblasts secrete both stimulatory and inhibitory factors, but the former are operative only on neu-expressing derivatives of the hematopoietic lines.
DISCUSSION
The major question addressed in the present work is whether it is feasible to use a putative receptor for a systematic screening that will lead to detection of its ligand. Answering this question is increasingly important as more and more putative receptors, most of them products of protooncogenes, are being identified. The definitive proof of suspected ligand-receptor relationships must rely on binding or chemical crosslinking of a radiolabeled ligand to its receptor. However, this approach is not practical when dealing with a .2F5 murine macrophages, either infected or uninfected with the neu gene, were grown to 80% confluency in 96-well dishes and then starved for 2 days in 0.5% calf serum in aMEM medium without CSF-1. BAF-3 murine prepro-B cells plated into a 96-well dish at 2 x 105 cells per ml in 0.5% calf serum (in RPMI medium). Interleukin 3 and CSF-1 were from media conditioned by Wehi-3 and L929 cells, respectively, and were added at 1:10 dilution. The conditioned medium from Rat-1-EJ cells was used at a final protein concentration of 0.1 mg/ml. The proliferative response was assayed by means of a colorimetric determination of the uptake of the mitochondrial dye MTT (24) . Results of triplicate determinations are given as mean ± SD and are expressed as percentage ofthe response obtained with the corresponding hematopoietic growth factor. Qualitatively identical results were obtained twice with BAF-3 cells and three times with BAC1.2F5 cells. ND, not determined.
Proc. NatL Acad. Sci. USA 86 (1989) 0-still unidentified molecule and with large numbers ofpotential biological sources of ligand. As a practical alternative, we sought to establish several independent ligand detection assays that are based on later steps of the ligand-receptor interaction rather than on the initial binding. Although indirect, such tests offer the advantage of ligand detection in crude unfractionated biological fluids.
Aiming at the ligand for the neu protooncogene product, we have used the structurally related EGF receptor as a model system to test the reliability, sensitivity, and specificity of each detection assay and then applied each assay to the neu system. The following lines of evidence collectively imply that a candidate ligand for pl85neu is present in medium conditioned by cultured fibroblasts that are transformed by a ras oncogene. (i) pl85feU is down-regulated in a temperaturedependent and suramin-sensitive manner by conditioned medium from ras-transformed cells but not by other media.
(ii) The catalytic kinase function of pl85eu is stimulated in vitro in a suramin-sensitive but temperature-independent process by the above-mentioned conditioned medium. A truncated receptor that lacks the ligand-binding domain is not affected. (iii) An increased phosphorylation on tyrosine residues of pl85neu is induced in vivo by conditioned medium from ras-transformed cells but not by media conditioned by other cells. The increase is seen in mesenchymal, hematopoietic, and epithelial cells, including EGF receptor-deficient cells. (iv) Transduction of the neu gene into hematopoietic cells renders them mitotically responsive to conditioned medium from ras-transformed fibroblasts.
We must consider the possibility that the observed effects are due to a factor that acts only indirectly on pl85neU. Transmodulation of EGF receptors through the activation of protein kinase C represents one well-characterized mechanism (39) . Thus, tyrosine phosphorylation of pl85neu is rapidly induced through activation of the kinase of EGF receptor (30, 31) . Since both TGF-a (40) and a PDGF-like factor (unpublished observation) are present in medium conditioned by ras-transformed cells, trans-modulation rather than direct activation of pl85neu may have potentially contributed to the observed effects. However, under the conditions used to obtain the aforementioned lines of evidence, neither PDGF, EGF, nor the EGF analogue TGF-a, induced the down-regulation response or stimulation of the catalytic function of pl85neu in vitro. Furthermore, detection of elevated tyrosine phosphorylation of pl85neu in epithelial cells that do not express either the PDGF or EGF receptor, and the selective mitotic responsiveness of neu-expressing hematopoietic cells also exclude their involvement.
It remains possible though unlikely that an as yet unknown factor is responsible for the observed biological effects, acting through a receptor other than pl85neu. Such a receptor would need to be broadly expressed in mesenchymal (Fig. 3 ) and hematopoietic cells (Fig. 4) . However, the differential activation of intact pl85neu compared with its truncated ectodomain-deficient forms (Figs. 2 and 3B ) strongly suggests that the putative ligand binding domain indeed directly mediates kinase activation by the factor of the conditioned medium. In the end, we cannot rule out absolutely the possibility that our results are due to a factor other than the neu ligand. The ultimate proof, as already discussed, will depend on the availability of a purified factor.
